Comparison of fixed and flexible progestin-primed ovarian stimulation protocols to prevent premature luteinization in patients with diminished ovarian reserve

Durdağ, Gülşen Doğan; Aytaç, Pınar Çağlar; Yağınç, Didem Alkaş; Yetkinel, Selçuk; Çok, Tayfun; Şimşek, Elif

doi:10.1007/s00404-023-07071-z

Cited by 3 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kalafat et al administered 10 mg-a-day of medroxyprogesterone acetate (MPA) to patients who had undergone OS for FP and found no differences between the two protocols in terms of number of cycles without oocyte retrieval, MII obtained or incidence of premature LH surge [6]. Similarly, Doğan Durdağ et al reported similar numbers of MII and incidence of premature luteinization and no differences in the number of two pronuclear zygotes and clinical pregnancy rate per transfer [7].…”

Section: Generalmentioning

confidence: 99%

Progestin-primed ovarian stimulation

Giles,

Cruz,

Garcia-Velasco

2024

Current Opinion in Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Purpose of review The use of progestins as pituitary suppressors has increased progressively, along with more detailed indications for their use, thereby consolidating an alternative approach to the personalization of ovarian stimulation. Recent findings Based on the ability of progesterone to inhibit ovulation, progestins have been used in ovarian stimulation (OS) follicular protocols to prevent a luteinizing hormone surge in patients undergoing in vitro fertilization (IVF), as an alternative to gonadotropin-releasing hormone (GnRH) analogue administration. This review explores the different types of progestogen protocols and their efficacy depending on the type of population or reproductive procedure in which they are administered and in comparison with that of GnRH analogues. Their effect on oocytes and embryos and their safety and cost-effectiveness are also analyzed. Summary Progestins have proven their effectiveness as a gonadotropin adjuvant in terms of ovarian response, reproductive outcome, and safety. In addition, they offer the convenience of oral administration and a lower cost than GnRH analogues. Whereas oocytes or embryos should be vitrified as it displaces the receptive period with the consequent asynchrony between embryo and endometrium. The evidence endorses progestins as a more friendly approach to OS, especially when frozen-thawed embryo transfer is planned.

show abstract

Section: Generalmentioning

confidence: 99%